Last reviewed · How we verify
NCT07123493
Engineered T-Cell Therapy for Patients With ALPP-Positive Advanced Solid Tumors
EARLY_PHASE1 trial testing Anti ALPP CAR-T cells treatment in Recurrent or Metastatic Solid Tumors With Positive ALPP in 1 participant. Terminated before completion.
30 December 2025
Quick facts
| Lead sponsor | Haifeng Qin |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 1 |
| Start date | 28 August 2025 |
| Primary completion | 30 December 2025 |
| Estimated completion | 30 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Anti ALPP CAR-T cells treatment — full drug profile →
Conditions studied
- Recurrent or Metastatic Solid Tumors With Positive ALPP — all drugs for Recurrent or Metastatic Solid Tumors With Positive ALPP →
Sponsor
Haifeng Qin — full company profile →
Who can join
Adults 18 to 70, any sex, with Recurrent or Metastatic Solid Tumors With Positive ALPP. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of ALPP CAR-T cells in patients with ALPP-positive recurrent or metastatic solid tumors who have progressed after prior therapies. The primary objective is to determine the maximum tolerated dose (MTD), with a secondary aim to assess preliminary clinical efficacy in solid tumors.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07123493
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Anti ALPP CAR-T cells treatment
Trials testing the same drug.
- NCT07108140 — Engineered T-cell Therapy for Patients With ALPP-Positive Advanced Solid Tumors · EARLY_PHASE1 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07123493 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Haifeng Qin
- Last refreshed: 28 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07123493.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing